maymetsi 50 mg/850 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 100 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 50 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 25 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
juzina 100 mg filmom obalené tablety
gedeon richter plc., maďarsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin stada 100 mg filmom obalené tablety
stada arzneimittel ag, nemecko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin glenmark 100 mg
glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin glenmark 50 mg
glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin glenmark 25 mg
glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.